COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from post-Golgi compartments.
Impaired biosynthetic processing of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel, constitutes the most common cause of CF. Recently, we have identified a distinct category of mutation, caused by premature stop codons and frameshift mutations, which manifests in diminished expression of COOH-terminally truncated CFTR at the cell surface. Although the biosynthetic processing and plasma membrane targeting of truncated CFTRs are preserved, the turnover of the complex-glycosylated mutant is sixfold faster than its wild-type (wt) counterpart. Destabilization of the truncated CFTR coincides with its enhanced susceptibility to proteasome-dependent degradation from post-Golgi compartments globally, and the plasma membrane specifically, determined by pulse-chase analysis in conjunction with cell surface biotinylation. Proteolytic cleavage of the full-length complex-glycosylated wt and degradation intermediates derived from both T70 and wt CFTR requires endolysosomal proteases. The enhanced protease sensitivity in vitro and the decreased thermostability of the complex-glycosylated T70 CFTR in vivo suggest that structural destabilization may account for the increased proteasome susceptibility and the short residence time at the cell surface. These in turn are responsible, at least in part, for the phenotypic manifestation of CF. We propose that the proteasome-ubiquitin pathway may be involved in the peripheral quality control of other, partially unfolded membrane proteins as well.
Benharouga
M
M
Program in Lung and Cell Biology, The Hospital for Sick Children, 555 University Ave., Toronto M5G 1X8, Ontario, Canada.
Haardt
M
M
Kartner
N
N
Lukacs
G L
GL
D000818:Animals; D020126:Brefeldin A / Q000494:pharmacology; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism*; D018388:Codon, Terminator / Q000235:genetics; D006224:Cricetinae; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011992:Endosomes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D016368:Frameshift Mutation / Q000235:genetics; D006031:Glycosylation; D006056:Golgi Apparatus / Q000378:metabolism*; D007700:Kinetics; D008247:Lysosomes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology; D046988:Proteasome Endopeptidase Complex; D017510:Protein Folding; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D021381:Protein Transport; D017384:Sequence Deletion / Q000235:genetics*; D013696:Temperature; D013816:Thermodynamics; D014452:Ubiquitins / Q000378:metabolism
D018388:Codon, Terminator; D009097:Multienzyme Complexes; D010446:Peptide Fragments; D011480:Protease Inhibitors; D014452:Ubiquitins; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D020126:Brefeldin A; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex